Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/ADMA Biologics faces investigation over alleged securities fraud and channel stuffing claims.
ADMA
$8.62
-$0.06 -0.75%

ADMA Biologics faces investigation over alleged securities fraud and channel stuffing claims.

Market News
02 Apr 2026
PRNewsWire
View Source
Bearish
pluang ai news

Pomerantz LLP is investigating ADMA Biologics following a report accusing the company of inflating revenue through channel stuffing and undisclosed related party sales. The allegations claim ADMA's reported 20% revenue growth in 2025 was false, with actual revenues declining 3%. After the report, ADMA's stock dropped 16.63%. The investigation will determine if ADMA and its executives engaged in securities fraud or unlawful practices, potentially leading to legal action and financial consequences for the company.

More News (ADMA)

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Law Offices of Howard G. Smith reminds investors of approaching deadlines to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege the companies made f...

Market News
Bearish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App